Critical limb ischemia (CLTI) represents the most advanced stage of peripheral artery disease, where blood flow to the leg or foot is so severely reduced that tissue viability is threatened. Unlike earlier-stage claudication, which is often managed conservatively, CLTI generally requires urgent evaluation and a coordinated treatment pathway aimed at restoring adequate blood flow before irreversible tissue damage occurs. Understanding how this pathway typically unfolds can help patients and families recognize why prompt care matters.
Recognizing the Signs of Critical Limb Ischemia
CLTI is characterized by ischemic rest pain — pain in the foot or toes that occurs even without exertion, often worsening at night and sometimes improving when the leg is hung over the edge of a bed — along with non-healing wounds, ulcers, or tissue loss in the affected limb. These findings represent red-flag symptoms that warrant seeking immediate medical care rather than waiting for a routine appointment, since delayed evaluation in this stage of disease carries a meaningfully higher risk of limb loss.
Initial Evaluation: Confirming the Diagnosis and Extent
Once CLTI is suspected, evaluation typically includes the ankle-brachial index, though this measurement can be less reliable in patients with heavily calcified vessels, prompting additional tests such as toe pressures or duplex ultrasound. Imaging, often CT angiography or catheter-based angiography, is used to map the full extent and location of arterial blockage, since CLTI frequently involves disease at multiple levels, including both larger inflow vessels and smaller below-the-knee arteries.
Revascularization: Restoring Blood Flow
The central goal of CLTI treatment is revascularization, restoring adequate blood flow to the affected limb, and this can be pursued through either endovascular (catheter-based) or surgical bypass approaches, depending on the pattern and location of disease, the patient's overall surgical risk, and available conduit for a bypass if needed. Endovascular options may include angioplasty, stenting, and atherectomy to debulk calcified plaque, sometimes extending to below-the-knee vessels where smaller balloon and stent technologies are used. The choice between endovascular and surgical approaches is individualized and often made collaboratively within a multidisciplinary limb salvage team.
Why a Multidisciplinary Approach Matters
CLTI frequently occurs in patients with additional health complexities, including diabetes and kidney disease, and successful limb salvage often depends on more than restoring blood flow alone. Wound care specialists, podiatrists, infectious disease input for any associated infection, and vascular surgeons or interventionalists often work together, since addressing the vascular supply, the wound itself, and any infection simultaneously tends to produce better outcomes than treating any single element in isolation.
Device-Based Tools Used in CLTI Revascularization
Endovascular treatment of CLTI often draws on the same device categories used in less severe PAD, including angioplasty balloons, self-expanding nitinol stents, drug-coated balloon technology, and atherectomy systems for debulking calcified plaque, sometimes extended to smaller below-the-knee vessels depending on the disease pattern. These devices, including INVAMED's Extender balloon platform, Atlas Peripheral Stent System, and TemREN Rotablator, are described in more detail on the peripheral arterial disease page, with the specific approach determined by the treating team based on the individual patient's anatomy and overall condition.
What role does wound care play in critical limb ischemia treatment?
Restoring blood flow is often necessary but not always sufficient on its own; coordinated wound care, and treatment of any associated infection, typically plays an important complementary role in achieving limb salvage. This is a key reason multidisciplinary limb salvage teams are frequently involved in CLTI management.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.